Deligne C - Search Results

1

Personalized Immunotherapies for Type 1 Diabetes: Who, What, When, and How?

Deligne C, You S, Mallone R. Deligne C, et al. J Pers Med. 2022 Mar 29;12(4):542. doi: 10.3390/jpm12040542. J Pers Med. 2022. PMID: 35455658 Free PMC article. Review.

2

Oral Fc-Coupled Preproinsulin Achieves Systemic and Thymic Delivery Through the Neonatal Fc Receptor and Partially Delays Autoimmune Diabetes.

Corcos N, Culina S, Deligne C, Lavaud C, You S, Mallone R. Corcos N, et al. Among authors: deligne c. Front Immunol. 2021 Aug 10;12:616215. doi: 10.3389/fimmu.2021.616215. eCollection 2021. Front Immunol. 2021. PMID: 34447366 Free PMC article.

3

Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?

Deligne C, Milcent B, Josseaume N, Teillaud JL, Sibéril S. Deligne C, et al. Front Immunol. 2017 Aug 14;8:950. doi: 10.3389/fimmu.2017.00950. eCollection 2017. Front Immunol. 2017. PMID: 28855903 Free PMC article. Review.

4

Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients.

Milcent B, Josseaume N, Riller Q, Giglioli I, Rabia E, Deligne C, Latouche JB, Hamieh M, Couture A, Toutirais O, Lone YC, Jeger-Madiot R, Graff-Dubois S, Amorim S, Loiseau P, Toubert A, Brice P, Thieblemont C, Teillaud JL, Sibéril S. Milcent B, et al. Among authors: deligne c. Cancer Immunol Immunother. 2019 Oct;68(10):1561-1572. doi: 10.1007/s00262-019-02389-7. Epub 2019 Sep 7. Cancer Immunol Immunother. 2019. PMID: 31494742 Free PMC article.

5

[The Janus face of monoclonal antibodies in oncology: passive immunity and vaccination].

Deligne C, Teillaud JL. Deligne C, et al. Med Sci (Paris). 2013 Jan;29(1):57-63. doi: 10.1051/medsci/2013291014. Epub 2013 Jan 25. Med Sci (Paris). 2013. PMID: 23351695 Free article. Review. French.

6

A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.

Casadesús AV, Deligne C, Diallo BK, Sosa K, Josseaume N, Mesa C, León K, Hernández T, Teillaud JL. Casadesús AV, et al. Among authors: deligne c. Oncoimmunology. 2020 Jun 2;9(1):1770565. doi: 10.1080/2162402X.2020.1770565. Oncoimmunology. 2020. PMID: 32923126 Free PMC article.

7

Macrophages and Extracellular Matrix in Breast Cancer: Partners in Crime or Protective Allies?

Deligne C, Midwood KS. Deligne C, et al. Front Oncol. 2021 Feb 24;11:620773. doi: 10.3389/fonc.2021.620773. eCollection 2021. Front Oncol. 2021. PMID: 33718177 Free PMC article. Review.

8

Matrix-Targeting Immunotherapy Controls Tumor Growth and Spread by Switching Macrophage Phenotype.

Deligne C, Murdamoothoo D, Gammage AN, Gschwandtner M, Erne W, Loustau T, Marzeda AM, Carapito R, Paul N, Velazquez-Quesada I, Mazzier I, Sun Z, Orend G, Midwood KS. Deligne C, et al. Cancer Immunol Res. 2020 Mar;8(3):368-382. doi: 10.1158/2326-6066.CIR-19-0276. Epub 2020 Jan 15. Cancer Immunol Res. 2020. PMID: 31941671 Free PMC article.

9

Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice.

Deligne C, Metidji A, Fridman WH, Teillaud JL. Deligne C, et al. Leukemia. 2015 Apr;29(4):947-57. doi: 10.1038/leu.2014.275. Epub 2014 Sep 18. Leukemia. 2015. PMID: 25231744

10

[Anti-tumor monoclonal antibodies: new insights to elicit a long-term immune response].

Deligne C, Gros L. Deligne C, et al. Med Sci (Paris). 2019 Dec;35(12):982-989. doi: 10.1051/medsci/2019194. Epub 2020 Jan 6. Med Sci (Paris). 2019. PMID: 31903903 Free article. Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page